Navigation Links
Clevudine in Medical News

Pharmasset to Present at Two Upcoming Investor Conferences

...eatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America, Europe, Japan and Taiwan. clevudine is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir....

Pharmasset to Present at Two Upcoming Investor Conferences

...ine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatme...

Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference

...ine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatme...

Pharmasset Reports Financial Results for Quarter Ended March 31, 2008

...a $2.9 million increase in Phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B virus (HBV) infection, a $1.2 mill...e third calendar quarter of 2008. -- Completing HBV patient enrollment for clevudine Phase 3 registration studies in the second calendar half of 2008. -- I...

Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales

... their successful product launches." "Pharmasset intends to commercialize clevudine for the treatment of chronic hepatitis B infection," stated Schaefer Price,...hase 3 clinical trials for product registration in the Americas and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmace...

Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C

...t candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an orally admin...

Pharmasset's Underwriters Release Shares from Lock-Up

... product candidates. Clevudine, for the treatment of chronic HBV infection, is in Phase 3 clinical trials for registration in the Americas and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatme...
Clevudine in Medical Technology

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

- Company will increase focus on HCV pipeline - Conference call at 8:00 AM ET today PRINCETON, N.J., April 20 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announced today that after a discussion with its independent Data Safety Monitoring Board (DSMB) and the FDA, the co...

Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

96-week comparative study of Clevudine versus Viread(R) versus Clevudine+Viread(R) in 150 patients with chronic hepatitis B PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, In...

Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART

PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announces that interim results of physician-sponsored studies of clevudine for the treatment of chronic hepatitis B virus (HBV) and both preclinical and clinical results of R7128 for the treatment of chronic h...

Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV

-Two 48-week Superiority Studies versus Hepsera(R) in Patients with Chronic Hepatitis B- -Studies will also Assess Clevudine's Sustained Virologic Response Rate for HBV- PRINCETON, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Pharmasset, In...

Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL

The 42nd Annual Meeting of the European Association for the Study of the Liver PRINCETON, N.J., April 03, 2007 /PRNewswire/ -- Pharmasset announced today that presentations of preclinical studies of Clevudine for the treatment of hepatitis B (HBV) and PSI-6130, the parent molecule of R7128, for th...

Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop

PRINCETON, N.J., June 14, 2007 /PRNewswire-FirstCall/ -- Pharmasset, Inc. , a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, announced today that scientific data presentations about Clevudine and Racivir were ma...

Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)

...eatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America, Europe, Japan and Taiwan. clevudine is already approved for HBV in South Korea and the Philippines. It is marketed in Korea by Bukwang Pharmaceuticals under the brand name Levovir. R7128...

Pharmasset Reports Fiscal Year End 2008 Financial Results

... Pipeline Update and 2008 Highlights clevudine During 2008, new data from multiple invest...gator sponsored studies supported the potential of clevudine to treat hepatitis B (HBV), including its use in l...(R)). Management believes the unique attributes of clevudine will help to differentiate it in the marketplace, ...

Pharmasset Reports Financial Results for Quarter Ended June 30, 2008

...clinical trial expenses to support registration of clevudine for the treatment of chronic hepatitis B virus (HB...st quarter. The ANRS sponsored study investigating clevudine in combination with Viread(R) in HBV is a very exc... -- Announced initiation of a combination study of clevudine and Viread(R) for HBV by the French National A...

Pharmasset Reports First Fiscal Quarter 2008 Financial Results

...a $7.0 million increase in Phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B virus (HBV) infection, as well as ...April 23-27, 2008 in Milan, Italy. -- Complete HBV patient enrollment for clevudine Phase 3 registration clinical trials in the second calendar half of 20...
Clevudine in Biological News

Weill Cornell science briefs June/July 2008

...s NewYork-Presbyterian/Weill Cornell clinician-scientists are studying how a new drug might be used to treat chronic hepatitis B infection (HBV). clevudine is a compound that may provide a longer lasting viral suppression after treatment is stopped, compared to drugs currently prescribed to treat HBV. Thi...
Clevudine in Biological Technology

Pharmasset Reports Fiscal Second Quarter 2009 Financial Results

...marily the result of an increase in phase 3 registration study expenses for clevudine for the treatment of chronic hepatitis B infection, as well as increased pr...nnounced that it had voluntarily halted its phase 3 registration studies of clevudine for the treatment of chronic hepatitis B infection; On March 31, 20...

Pharmasset Reports Fiscal First Quarter 2009 Financial Results

...n phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B (HBV) inf...first quarter of 2009; -- Complete enrollment of clevudine registration trials at end of first quarter of 200...d South America and Europe, among other countries. clevudine is already approved for HBV in South Korea and mar...

Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients

...ine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatme...

Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th

...t candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatme...

Pharmasset Reports Fiscal Year End 2007 Financial Results

...n Phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B virus (HB...n 2008 by completing HBV patient enrollment of the clevudine Phase 3 clinical trials for registration in the Am...07 Highlights -- Initiated HBV patient dosing of clevudine Phase 3 clinical trials for registration in th...

Pharmasset Appoints Michael Rogers as Chief Development Officer

...t candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatme...

Pharmasset to Present at Three Investor Conferences in November 2007

...t candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatme...

Pharmasset Accesses up to $30 Million of Working Capital

...th our existing cash position, this financing is expected to fully fund the clevudine Phase 3 registration studies through the New Drug Application filing with t... is in Phase 3 clinical trials for registration in the Americas and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmace...

Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th

...ates. Clevudine, for the treatment of chronic HBV infection, is expected to enter Phase 3 clinical trials for registration in the Americas and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals under the brand name Levovir. R7128, an oral treatment for chronic ...

Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses

...ates. Clevudine, for the treatment of chronic HBV infection, is expected to enter Phase 3 clinical trials for registration in the Americas and Europe. clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals under the brand name Levovir. R7128, an oral treatment for chronic ...
Other Tags
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
Other Contents